J2 Capital Management Inc Takes $596,000 Position in GSK plc (NYSE:GSK)

J2 Capital Management Inc purchased a new stake in shares of GSK plc (NYSE:GSK - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 17,613 shares of the pharmaceutical company's stock, valued at approximately $596,000.

Other large investors also recently modified their holdings of the company. FMR LLC raised its position in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of GSK during the second quarter worth $52,487,000. Fisher Asset Management LLC lifted its holdings in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock valued at $759,425,000 after buying an additional 870,449 shares during the last quarter. Hotchkis & Wiley Capital Management LLC grew its position in GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company's stock worth $144,803,000 after acquiring an additional 833,080 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in GSK by 33.8% during the second quarter. Dimensional Fund Advisors LP now owns 2,256,320 shares of the pharmaceutical company's stock worth $86,875,000 after buying an additional 569,614 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

GSK has been the subject of a number of recent analyst reports. Jefferies Financial Group cut shares of GSK from a "buy" rating to a "hold" rating and decreased their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a report on Monday, January 13th. Finally, Guggenheim lowered GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat, GSK currently has a consensus rating of "Moderate Buy" and an average target price of $43.25.

GSK Price Performance

Shares of GSK stock traded up $0.02 during trading on Friday, hitting $33.46. The company had a trading volume of 3,930,425 shares, compared to its average volume of 2,865,091. The firm has a market capitalization of $69.34 billion, a P/E ratio of 21.72, a price-to-earnings-growth ratio of 1.44 and a beta of 0.63. GSK plc has a one year low of $31.72 and a one year high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The stock's 50-day moving average price is $34.02 and its 200 day moving average price is $37.98.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were issued a dividend of $0.3928 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 annualized dividend and a yield of 4.70%. This is an increase from GSK's previous quarterly dividend of $0.38. GSK's dividend payout ratio is 96.10%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.